ArticleJournal of ophthalmology2025
Reinterventions After PreserFlo Implantation: A Report on Results in Clinical Practice.
Article in Journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The PreserFlo MicroShunt is an effective surgical procedure for intraocular pressure (IOP) control in glaucoma. This study focuses on the rate of reinterventions after PreserFlo implantation, as well as exploring possible risk factors for reintervention. Methods: This retrospective study included all patients undergoing PreserFlo implantation in our center between March 2021 and March 2023. Surgery was performed as per the manufacturer's recommendations and combined with mitomycin C (MMC) application (0.2 mg/mL, 2 min). Clinical data before the surgical procedure, surgical reinterventions, IOP, the use of hypotensive drugs, and the results of visual field testing were recorded and analyzed. Results: 91 eyes of 84 patients undergoing PreserFlo implantation were included. 48 eyes had primary open-angle glaucoma (POAG), 23 eyes pseudoexfoliation glaucoma, and the rest myopic, pigmentary or secondary glaucoma. At least one additional surgical procedure was required in 31 eyes (34.1%); 13 eyes required more than one procedure. Approximately 45% of the additional procedures had to be performed in the first 3 months after PreserFlo implantation. The additional procedures performed were 35 bleb revision surgeries, four vitrectomies, eight iStent implantations, four conjunctival sutures due to bleb leak, five nonpenetrating deep sclerotomies, and two PreserFlo tube repositioning surgeries. There was a statistically significant higher rate of reinterventions in eyes with pigmentary or pseudoexfoliative glaucoma (14/26, 53.8%) compared to eyes with POAG (12/48, 25%) ( Conclusions: Surgical reinterventions were required in a third of the eyes implanted with PreserFlo. Reintervention rate was higher in eyes treated with ≥ 3 drugs. Surgeons should consider adding additional measures to prevent fibrosis when implanting PreserFlo in these eyes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.